Your browser doesn't support javascript.
loading
Outcome of BCG Vaccination in ADA-SCID Patients: A 12-Patient Series.
Canarutto, Daniele; Oltolini, Chiara; Barzaghi, Federica; Calbi, Valeria; Migliavacca, Maddalena; Tucci, Francesca; Gallo, Vera; Consiglieri, Giulia; Ferrua, Francesca; Recupero, Salvatore; Cervi, Maria Celia; Al-Mousa, Hamoud; Pituch-Noworolska, Anna; Tassan Din, Chiara; Scarpellini, Paolo; Silvani, Paolo; Fossati, Claudia; Casiraghi, Miriam; Cirillo, Daniela Maria; Castagna, Antonella; Bernardo, Maria Ester; Aiuti, Alessandro; Cicalese, Maria Pia.
Afiliación
  • Canarutto D; Faculty of Medicine and Surgery, Vita-Salute S. Raffaele University, 20132 Milan, Italy.
  • Oltolini C; San Raffaele Telethon Institute for Gene Therapy (SR-Tiget), IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy.
  • Barzaghi F; Pediatric Immunohematology Unit and BMT Program, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy.
  • Calbi V; Clinic of Infectious Diseases, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy.
  • Migliavacca M; San Raffaele Telethon Institute for Gene Therapy (SR-Tiget), IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy.
  • Tucci F; Pediatric Immunohematology Unit and BMT Program, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy.
  • Gallo V; San Raffaele Telethon Institute for Gene Therapy (SR-Tiget), IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy.
  • Consiglieri G; Pediatric Immunohematology Unit and BMT Program, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy.
  • Ferrua F; San Raffaele Telethon Institute for Gene Therapy (SR-Tiget), IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy.
  • Recupero S; Pediatric Immunohematology Unit and BMT Program, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy.
  • Cervi MC; San Raffaele Telethon Institute for Gene Therapy (SR-Tiget), IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy.
  • Al-Mousa H; Pediatric Immunohematology Unit and BMT Program, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy.
  • Pituch-Noworolska A; San Raffaele Telethon Institute for Gene Therapy (SR-Tiget), IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy.
  • Tassan Din C; Pediatric Immunohematology Unit and BMT Program, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy.
  • Scarpellini P; San Raffaele Telethon Institute for Gene Therapy (SR-Tiget), IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy.
  • Silvani P; Pediatric Immunohematology Unit and BMT Program, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy.
  • Fossati C; San Raffaele Telethon Institute for Gene Therapy (SR-Tiget), IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy.
  • Casiraghi M; Pediatric Immunohematology Unit and BMT Program, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy.
  • Cirillo DM; San Raffaele Telethon Institute for Gene Therapy (SR-Tiget), IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy.
  • Castagna A; Pediatric Immunohematology Unit and BMT Program, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy.
  • Bernardo ME; Pediatric Infectious Diseases Division, Department of Pediatrics, Ribeirao Preto Medical School, University of Sao Paulo, Sao Paulo 05508-000, Brazil.
  • Aiuti A; Department of Pediatrics, King Faisal Specialist Hospital and Research Center, Riyadh 11564, Saudi Arabia.
  • Cicalese MP; Department of Immunology, University Children's Hospital, 30-663 Krakow, Poland.
Biomedicines ; 11(7)2023 Jun 24.
Article en En | MEDLINE | ID: mdl-37509449
Vaccination with Bacillus Calmette-Guérin (BCG) can be harmful to patients with combined primary immunodeficiencies. We report the outcome of BCG vaccination in a series of twelve patients affected by adenosine deaminase deficiency (ADA-SCID). BCG vaccination resulted in a very high incidence of complications due to uncontrolled replication of the mycobacterium. All patients who developed BCG-related disease were treated successfully and remained free from recurrence of disease. We recommend the prompt initiation of enzyme replacement therapy and secondary prophylaxis to reduce the risk of BCG-related complications in ADA-SCID patients.
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Biomedicines Año: 2023 Tipo del documento: Article País de afiliación: Italia Pais de publicación: Suiza
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Biomedicines Año: 2023 Tipo del documento: Article País de afiliación: Italia Pais de publicación: Suiza